44 results on '"Korell, Felix"'
Search Results
2. Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation
3. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
4. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
5. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
6. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics
7. Supplementary Video S12 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
8. Supplementary Figure S6 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
9. Data from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
10. Supplementary Methods 1 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
11. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
12. Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation
13. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
14. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood
15. Completion rate and impact on physician–patient relationship of video consultations in medical oncology: a randomised controlled open-label trial
16. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC
17. 439 Cardiovascular safety of chimeric antigen receptor (CAR) T cell therapy
18. 310 Targeted delivery of a VEGF-blocking scFv to enhance CAR-T cell potency
19. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CARin peripheral blood
20. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
21. Abstract 4098: Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics
22. Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas
23. Bcl‐x Las prognostic marker and potential therapeutic target in cholangiocarcinoma
24. RELB activation drives tumour aggressiveness and predicts prognosis in hepatocellular carcinoma
25. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
26. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
27. Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
28. Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)
29. Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy
30. CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR
31. Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation
32. Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy
33. Robotic Surgery beim Endometriumkarzinom – Vergleich verschiedener Operationszugänge und -verfahren bezüglich peri- und postoperativer Morbidität
34. Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.
35. EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients
36. Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
37. Analysis of Symptoms of COVID-19 Positive Patients and Potential Effects on Initial Assessment
38. Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)
39. Feasibility and sociopsychological impact of video consultations in medical oncology - a randomized controlled open label trial
40. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
41. Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.
42. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.
43. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
44. Bcl-x L as prognostic marker and potential therapeutic target in cholangiocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.